Phase II data bring Blueprint closer to major market expansion for Ayvakit

With positive initial data for Ayvakit in indolent systemic mastocytosis, Blueprint is moving into position to expand its only approved drug into a much larger patient population while sticking to its strategy of focusing on genetically defined subsets of cancer and rare diseases.

Blueprint Medicines Corp. (NASDAQ:BPMC) presented data from the first, dose-finding part of its Phase II PIONEER trial at the American Academy

Read the full 632 word article

How to gain access

Continue reading with a
two-week free trial.